Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico
The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. Material and Methods. A decision tree was developed in preterm groups [<29 and 29-32...
Spremljeno u:
| Izdano u: | Salud Pública de México |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Instituto Nacional de Salud Pública
2012
|
| Teme: | |
| Online pristup: | https://www.redalyc.org/articulo.oa?id=10623032007 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|